Clinical and Molecular Hepatology (대한간학회지)

The Korean Association for the Study of the Liver (대한간학회)
권호 표지
DOI QR코드

DOI QR Code

The association of leptin with severity of non-alcoholic fatty liver disease: A population-based study

  • Rotundo, Laura (Department of Medicine, Rutgers New Jersey Medical School) ;
  • Persaud, Alana (Department of Medicine, Rutgers New Jersey Medical School) ;
  • Feurdean, Mirela (Department of Medicine, Rutgers New Jersey Medical School) ;
  • Ahlawat, Sushil (Division of Gastroenterology and Hepatology, Rutgers New Jersey Medical School) ;
  • Kim, Hyun-seok (Department of Medicine, Rutgers New Jersey Medical School)
  • Received : 2018.01.26
  • Accepted : 2018.06.10
  • Published : 2018.12.25
⟨ Previous Next ⟩

Abstract

Background/Aims: Leptin is associated with metabolic disorders, which predispose one to non-alcoholic fatty liver disease (NAFLD). The role of leptin in NAFLD pathogenesis is not fully understood. We aim to investigate the association between serum leptin level and severity of NAFLD using U.S. nationally representative data. Methods: Data were obtained from the United States Third National Health and Nutrition Examination Survey. NAFLD was defined by ultrasound detection and severity of hepatic steatosis in the absence of other liver diseases. The severity of hepatic fibrosis was determined by NAFLD fibrosis score (NFS). We used multivariate survey-weighted generalized logistic regression to evaluate the association between leptin level and the degree of NAFLD. We also performed subgroup analyses by body mass index (lean vs. classic NAFLD). Results: Among 4,571 people, 1,610 (35%) had NAFLD. By ultrasound findings, there were 621 people with mild, 664 with moderate, and 325 with severe steatosis. There were 885 people with low NFS (<-1.455, no significant fibrosis), 596 with intermediate NFS, and 129 with high NFS (>0.676, advanced fibrosis). Leptin levels for normal, mild, moderate and severe steatosis were $10.7{\pm}0.3ng/mL$, $12.1{\pm}0.7ng/mL$, $15.6{\pm}0.8ng/mL$, $16{\pm}1.0ng/mL$, respectively (trend P-value<0.001). Leptin levels for low, intermediate, and high NFS were $11.8{\pm}0.5ng/mL$, $15.6{\pm}0.8ng/mL$, $28.5{\pm}3.5ng/mL$, respectively (trend P-value<0.001). This association remained significant even after adjusting for known demographic and metabolic risk factors. In the subgroup analysis, this association was only prominent in classic NAFLD, but not in lean NAFLD. Conclusions: Serum leptin level is associated with the severity of NAFLD, especially in classic NAFLD patients.

Keywords

References

  1. Fantuzzi G, Faggioni R. Leptin in the regulation of immunity, inflammation, and hematopoiesis. J Leukoc Biol 2000;68:437-446.
  2. Angulo P, Alba LM, Petrovic LM, Adams LA, Lindor KD, Jensen MD. Leptin, insulin resistance, and liver fibrosis in human nonalcoholic fatty liver disease. J Hepatol 2004;41:943-949. https://doi.org/10.1016/j.jhep.2004.08.020
  3. Testa R, Franceschini R, Giannini E, Cataldi A, Botta F, Fasoli A, et al. Serum leptin levels in patients with viral chronic hepatitis or liver cirrhosis. J Hepatol 2000;33:33-37. https://doi.org/10.1016/S0168-8278(00)80156-7
  4. Bouloumie A, Marumo T, Lafontan M, Busse R. Leptin induces oxidative stress in human endothelial cells. FASEB J 1999;13:1231-1238. https://doi.org/10.1096/fasebj.13.10.1231
  5. Ikejima K, Honda H, Yoshikawa M, Hirose M, Kitamura T, Takei Y, et al. Leptin augments inflammatory and profibrogenic responses in the murine liver induced by hepatotoxic chemicals. Hepatology 2001;34:288-297. https://doi.org/10.1053/jhep.2001.26518
  6. Saxena NK, Titus MA, Ding X, Floyd J, Srinivasan S, Sitaraman SV, et al. Leptin as a novel profibrogenic cytokine in hepatic stellate cells: mitogenesis and inhibition of apoptosis mediated by extracellular regulated kinase (Erk) and Akt phosphorylation. FASEB J 2004;18:1612-1614. https://doi.org/10.1096/fj.04-1847fje
  7. Bedogni G, Miglioli L, Masutti F, Tiribelli C, Marchesini G, Bellentani S. Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology 2005;42:44-52.
  8. Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology 2003;37:1202-1219. https://doi.org/10.1053/jhep.2003.50193
  9. Lazo M, Clark JM. The epidemiology of nonalcoholic fatty liver disease: a global perspective. Semin Liver Dis 2008;28:339-350. https://doi.org/10.1055/s-0028-1091978
  10. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016;64:73-84. https://doi.org/10.1002/hep.28431
  11. Kim HJ, Kim HJ, Lee KE, Kim DJ, Kim SK, Ahn CW, et al. Metabolic significance of nonalcoholic fatty liver disease in nonobese, nondiabetic adults. Arch Intern Med 2004;164:2169-2175. https://doi.org/10.1001/archinte.164.19.2169
  12. Cruz ACD, Bugianesi E, George J, Day CP, Liaquat H, Charatcharoenwitthaya P, et al. 379. Characteristics and long-term prognosis of lean patients with nonalcoholic fatty liver disease [Abstract]. Gastroenterology 2014;146:S-909.
  13. Uygun A, Kadayifci A, Yesilova Z, Erdil A, Yaman H, Saka M, et al. Serum leptin levels in patients with nonalcoholic steatohepatitis. Am J Gastroenterol 2000;95:3584-3589. https://doi.org/10.1111/j.1572-0241.2000.03297.x
  14. Dasarathy S, Yang Y, McCullough AJ, Marczewski S, Bennett C, Kalhan SC. Elevated hepatic fatty acid oxidation, high plasma fibroblast growth factor 21, and fasting bile acids in nonalcoholic steatohepatitis. Eur J Gastroenterol Hepatol 2011;23:382-388. https://doi.org/10.1097/MEG.0b013e328345c8c7
  15. Saxena NK, Ikeda K, Rockey DC, Friedman SL, Anania FA. Leptin in hepatic fibrosis: evidence for increased collagen production in stellate cells and lean littermates of ob/ob mice. Hepatology 2002;35:762-771. https://doi.org/10.1053/jhep.2002.32029
  16. Saxena NK, Saliba G, Floyd JJ, Anania FA. Leptin induces increased alpha2(I) collagen gene expression in cultured rat hepatic stellate cells. J Cell Biochem 2003;89:311-320. https://doi.org/10.1002/jcb.10494
  17. Elbadawy RA, Eleter EA, Helmy A, Al Ghamdi AS, Al-Mofleh I, Al Faleh FZ, et al. The role of leptin in non-alcoholic fatty liver disease. Saudi J Gastroenterol 2006;12:68-72. https://doi.org/10.4103/1319-3767.27848
  18. Chitturi S, Farrell G, Frost L, Kriketos A, Lin R, Fung C, et al. Serum leptin in NASH correlates with hepatic steatosis but not fibrosis: a manifestation of lipotoxicity? Hepatology 2002;36:403-409. https://doi.org/10.1053/jhep.2002.34738
  19. Chalasani N, Crabb DW, Cummings OW, Kwo PY, Asghar A, Pandya PK, et al. Does leptin play a role in the pathogenesis of human nonalcoholic steatohepatitis? Am J Gastroenterol 2003;98:2771-2776. https://doi.org/10.1111/j.1572-0241.2003.08767.x
  20. National Center for Health Statistics (NCHS). Plan and Operation of the Third National Health and Nutritional Examination Survey, 1988-94. Series 1: Programs and Collection Procedures. NCHS web site, . Accessed 11 Nov 2017.
  21. Kim D, Kim WR, Kim HJ, Therneau TM. Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States. Hepatology 2013;57:1357-1365. https://doi.org/10.1002/hep.26156
  22. Angulo P, Hui JM, Marchesini G, Bugianesi E, George J, Farrell GC, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 2007;45:846-854. https://doi.org/10.1002/hep.21496
  23. Lin ZH, Xin YN, Dong QJ, Wang Q, Jiang XJ, Zhan SH, et al. Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis. Hepatology 2011;53:726-736. https://doi.org/10.1002/hep.24105
  24. National Center for Health Statistics (NCHS). National Health and Nutrition Examination Survey III: Body Measurements (Anthropometry). NCHS web site, . Accessed 11 Nov 2017.
  25. National Center for Health Statistics (NCHS). Laboratory Procedures Used for the Third National Health and Nutrition Examination Survey (NHANES III), 1988-1994. 1996. NCHS web site, . Accessed 11 Nov 2017.
  26. Liangpunsakul S, Chalasani N. Serum vitamin D concentrations and unexplained elevation in ALT among US adults. Dig Dis Sci 2011;56:2124-2129. https://doi.org/10.1007/s10620-011-1707-x
  27. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001;285:2486-2497. https://doi.org/10.1001/jama.285.19.2486
  28. Ma Z, Gingerich RL, Santiago JV, Klein S, Smith CH, Landt M. Radioimmunoassay of leptin in human plasma. Clin Chem 1996;42(6 Pt 1):942-946.
  29. National Center for Health Statistics (NCHS). 2013-2014 Data Documentation, Codebook, and Frequencies. 2015. NCHS web site, . Accessed 11 Nov 2017.
  30. Lumley T. Analysis of complex survey samples. J Statistic Software 2004;9:1-19.
  31. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002;346:1221-1231. https://doi.org/10.1056/NEJMra011775
  32. Campbell B, Aguilar M, Bhuket T, Torres S, Liu B, Wong RJ. Females, Hispanics and older individuals are at greatest risk of developing metabolic syndrome in the US. Diabetes Metab Syndr 2016;10:230-233. https://doi.org/10.1016/j.dsx.2016.06.014
  33. Crespo CJ, Loria CM, Burt VL. Hypertension and other cardiovascular disease risk factors among Mexican Americans, Cuban Americans, and Puerto Ricans from the Hispanic Health and Nutrition Examination Survey. Public Health Rep 1996;111 Suppl 2:7-10.
  34. Brancati FL, Kao WH, Folsom AR, Watson RL, Szklo M. Incident type 2 diabetes mellitus in African American and white adults: the Atherosclerosis Risk in Communities Study. JAMA 2000;283:2253-2259. https://doi.org/10.1001/jama.283.17.2253
  35. Targher G, Rossini M, Lonardo A. Evidence that non-alcoholic fatty liver disease and polycystic ovary syndrome are associated by necessity rather than chance: a novel hepato-ovarian axis? Endocrine 2016;51:211-221. https://doi.org/10.1007/s12020-015-0640-8
  36. Ayonrinde OT, Olynyk JK, Beilin LJ, Mori TA, Pennell CE, de Klerk N, et al. Gender-specific differences in adipose distribution and adipocytokines influence adolescent nonalcoholic fatty liver disease. Hepatology 2011;53:800-809. https://doi.org/10.1002/hep.24097
  37. Neuschwander-Tetri BA, Clark JM, Bass NM, Van Natta ML, Unalp-Arida A, Tonascia J, et al. Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease. Hepatology 2010;52:913-924.
  38. Selthofer-Relatic K, Radic R, Stupin A, Sisljagic V, Bosnjak I, Bulj N, et al. Leptin/adiponectin ratio in overweight patients - gender differences. Diab Vasc Dis Res 2018;15:260-262. https://doi.org/10.1177/1479164117752491
  39. Liuzzi A, Savia G, Tagliaferri M, Lucantoni R, Berselli ME, Petroni ML, et al. Serum leptin concentration in moderate and severe obesity: relationship with clinical, anthropometric and metabolic factors. Int J Obes Relat Metab Disord 1999;23:1066-1073. https://doi.org/10.1038/sj.ijo.0801036
  40. Ben Ali S, Jemaa R, Ftouhi B, Kallel A, Feki M, Slimene H, et al. Relationship of plasma leptin and adiponectin concentrations with menopausal status in Tunisian women. Cytokine 2011;56:338-342. https://doi.org/10.1016/j.cyto.2011.06.026
  41. Tsochatzis EA, Papatheodoridis GV, Archimandritis AJ. Adipokines in nonalcoholic steatohepatitis: from pathogenesis to implications in diagnosis and therapy. Mediators Inflamm 2009;2009:831670.
  42. Lewis GF, Carpentier A, Adeli K, Giacca A. Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes. Endocr Rev 2002;23:201-229. https://doi.org/10.1210/edrv.23.2.0461
  43. Paradis V, Perlemuter G, Bonvoust F, Dargere D, Parfait B, Vidaud M, et al. High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: a potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis. Hepatology 2001;34(4 Pt 1):738-744. https://doi.org/10.1053/jhep.2001.28055
  44. Vos B, Moreno C, Nagy N, Fery F, Cnop M, Vereerstraeten P, et al. Lean non-alcoholic fatty liver disease (Lean-NAFLD): a major cause of cryptogenic liver disease. Acta Gastroenterol Belg 2011;74:389-394.
  45. Visser ME, Lammers NM, Nederveen AJ, van der Graaf M, Heerschap A, Ackermans MT, et al. Hepatic steatosis does not cause insulin resistance in people with familial hypobetalipoproteinaemia. Diabetologia 2011;54:2113-2121. https://doi.org/10.1007/s00125-011-2157-x
  46. Rahimi AR, Daryani NE, Ghofrani H, Taher M, Pashaei MR, Abdollahzade S, et al. The prevalence of celiac disease among patients with non-alcoholic fatty liver disease in Iran. Turk J Gastroenterol 2011;22:300-304. https://doi.org/10.4318/tjg.2011.0216
  47. Abenavoli L, Milic N, De Lorenzo A, Luzza F. A pathogenetic link between non-alcoholic fatty liver disease and celiac disease. Endocrine 2013;43:65-67. https://doi.org/10.1007/s12020-012-9731-y
  48. Staufer K, Halilbasic E, Trauner M, Kazemi-Shirazi L. Cystic fibrosis related liver disease--another black box in hepatology. Int J Mol Sci 2014;15:13529-13549. https://doi.org/10.3390/ijms150813529
  49. Margariti E, Deutsch M, Manolakopoulos S, Papatheodoridis GV. Non-alcoholic fatty liver disease may develop in individuals with normal body mass index. Ann Gastroenterol 2012;25:45-51.
  50. Kumar R, Rastogi A, Sharma MK, Bhatia V, Garg H, Bihari C, et al. Clinicopathological characteristics and metabolic profiles of nonalcoholic fatty liver disease in Indian patients with normal body mass index: do they differ from obese or overweight non-alcoholic fatty liver disease? Indian J Endocrinol Metab 2013;17:665-671.
  51. Ikejima K, Lang T, Zhang YJ, Yamashina S, Honda H, Yoshikawa M, et al. Expression of leptin receptors in hepatic sinusoidal cells. Comp Hepatol 2004;3 Suppl 1:S12. https://doi.org/10.1186/1476-5926-2-S1-S12
  52. Joseph AE, Saverymuttu S, al-Sam S, Cook MG, Maxwell JD. Comparison of liver histology with ultrasonography in assessing diffuse parenchymal liver disease. Clin Radiol 1991;43:26-31. https://doi.org/10.1016/S0009-9260(05)80350-2
  53. Brunt EM. Nonalcoholic steatohepatitis: definition and pathology. Semin Liver dis 2001;21:3-16. https://doi.org/10.1055/s-2001-12925
  54. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999;94:2467-2474. https://doi.org/10.1111/j.1572-0241.1999.01377.x
  55. Puustinen L, Boyd S, Mustonen H, Arkkila P, Arola J, Farkkila M. Prognostic value of clinical variables and liver histology for development of fibrosis and cirrhosis in autoimmune hepatitis. Scand J Gastroenterol 2017;52:321-327. https://doi.org/10.1080/00365521.2016.1253768
  56. Adams LA, Lymp JF, St Sauver J, Sanderson SO, Lindor KD, Feldstein A, et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005;129:113-121. https://doi.org/10.1053/j.gastro.2005.04.014
  57. Ong JP, Pitts A, Younossi ZM. Increased overall mortality and liverrelated mortality in non-alcoholic fatty liver disease. J Hepatol 2008;49:608-612. https://doi.org/10.1016/j.jhep.2008.06.018
  58. Polyzos SA, Aronis KN, Kountouras J, Raptis DD, Vasiloglou MF, Mantzoros CS. Circulating leptin in non-alcoholic fatty liver disease: a systematic review and meta-analysis. Diabetologia 2016;59:30-43. https://doi.org/10.1007/s00125-015-3769-3
  59. Saverymuttu SH, Joseph AE, Maxwell JD. Ultrasound scanning in the detection of hepatic fibrosis and steatosis. Br Med J (Clin Res Ed) 1986;292:13-15. https://doi.org/10.1136/bmj.292.6512.13
  60. Hernaez R, Lazo M, Bonekamp S, Kamel I, Brancati FL, Guallar E, et al. Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis. Hepatology 2011;54:1082-1090.

Cited by

  1. Telmisartan improves the metabolic, hematological and inflammasome indices in non-alcoholic fatty liver infiltration: A pilot open-label placebo-controlled study vol.16, pp.3, 2018, https://doi.org/10.29333/ejgm/104568
  2. Serum leptin in non-alcoholic fatty liver disease: Ambiguous clinical implications concerning cardiovascular disease vol.25, pp.3, 2018, https://doi.org/10.3350/cmh.2019.0034
  3. Adipokines: A Rainbow of Proteins with Metabolic and Endocrine Functions vol.27, pp.None, 2018, https://doi.org/10.2174/0929866527666200505214555
  4. Natural History of Nonalcoholic Fatty Liver Disease: Implications for Clinical Practice and an Individualized Approach vol.2020, pp.None, 2018, https://doi.org/10.1155/2020/9181368
  5. Target Deconvolution of Fenofibrate in Nonalcoholic Fatty Liver Disease Using Bioinformatics Analysis vol.2021, pp.None, 2021, https://doi.org/10.1155/2021/3654660
  6. Nutrigenetic Interactions Might Modulate the Antioxidant and Anti-Inflammatory Status in Mastiha-Supplemented Patients With NAFLD vol.12, pp.None, 2021, https://doi.org/10.3389/fimmu.2021.683028
  7. Till Death Do Us Part-The Multifaceted Role of Platelets in Liver Diseases vol.22, pp.6, 2021, https://doi.org/10.3390/ijms22063113
  8. Association between the severity of liver fibrosis and cardiovascular outcomes in patients with type 2 diabetes vol.36, pp.6, 2021, https://doi.org/10.1111/jgh.15387
  9. Current Perspectives on the Beneficial Effects of Soybean Isoflavones and Their Metabolites for Humans vol.10, pp.7, 2021, https://doi.org/10.3390/antiox10071064
  10. Role of Leptin in Non-Alcoholic Fatty Liver Disease vol.9, pp.7, 2018, https://doi.org/10.3390/biomedicines9070762
  11. Lipid Metabolism Disorders in the Comorbid Course of Nonalcoholic Fatty Liver Disease and Chronic Obstructive Pulmonary Disease vol.10, pp.11, 2021, https://doi.org/10.3390/cells10112978
  12. Recent Advances in Adipose Tissue Dysfunction and Its Role in the Pathogenesis of Non-Alcoholic Fatty Liver Disease vol.10, pp.12, 2018, https://doi.org/10.3390/cells10123300